A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Clinical trial NCT04236141 · TERMINATED
Trial details
- NCT number
- NCT04236141
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-10
- Primary completion
- 2021-07-12
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.